Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience

Publication date: Available online 5 April 2019Source: Gynecologic Oncology ReportsAuthor(s): Maria Rubinstein, Darragh Halpenny, Vicky Makker, Rachel N. Grisham, Carol Aghajanian, Karen CadooAbstractWomen with endometrial cancer (EC) frequently receive adjuvant paclitaxel and carboplatin (PC) chemotherapy. There is no standard first line chemotherapy at disease recurrence. Data extrapolated from ovarian cancer has suggested that patients with recurrent EC may benefit from further platinum-based chemotherapy. We performed a retrospective analysis of patients who were retreated with PC chemotherapy for recurrent EC at Memorial Sloan Kettering Cancer Center between January 2000 and December 2014. The median progression free survival (PFS) and overall survival (OS) were estimated using the Kaplan Meier method. Twenty patients were included in the analysis. Patients were re-treated with PC a median of 25 (8–79) months from their original PC. There were no complete responses, 10 (50%) patients had partial response (PR), 3 (15%) had stable disease, 2 (10%) had progression at best response and 5 (20%) were not evaluable by RECIST. A median of 6 cycles of PC were administered (2–9). Four patients (20%) transitioned to paclitaxel only due to carboplatin allergy. At the data cut off, one patient continued PC, and another was off therapy with PR. The remainder (N = 18, 90%) received a median of 2.5 (1–6) further lines of treatments. Median PFS and OS from re-trea...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research

Related Links:

Sialyl Lewis A (sLeA, also known as CA19-9), a tetrasaccharide selectively and highly expressed on advanced adenocarcinomas including colon, stomach, and pancreatic cancers, has long been considered as an attractive target for active and passive vaccination. While progress in antibodies targeting tumor-associated protein antigens resulted in an impressive array of therapeutics for cancer treatment, similar progress in exploiting tumor-associated carbohydrate antigens, such as sLeA, has been hampered by the lack of a detailed understanding of the singular characteristics of these antigens. We have addressed this issue by an...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Despite recent therapeutic advances, prostate cancer remains a leading cause of cancer-related death. A subset of castration-resistant prostate cancers become androgen receptor (AR) signaling independent and develop neuroendocrine prostate cancer (NEPC) features through lineage plasticity. These NEPC tumors, associated with aggressive disease and poor prognosis, are driven, in part, by aberrant expression of N-Myc, through mechanisms that remain unclear. Integrative analysis of the N-Myc transcriptome, cistrome, and interactome using in vivo, in vitro, and ex vivo models (including patient-derived organoids) identified a l...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Induction of memory CD8+ T cells is important for controlling infections such as malaria and HIV/AIDS and for cancer immunotherapy. Accurate assessment of antigen-specific (Ag-specific) CD8+ T cells is critical for vaccine optimization and for defining correlates of protection. However, conditions for determining Ag-specific CD8+ T cell responses ex vivo using intracellular cytokine staining (ICS) may be variable, especially in humans with complex antigens. Here, we used an attenuated whole parasite malaria vaccine model in humans and various experimental infections in mice to show that the duration of antigenic stimulatio...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
New J. Chem., 2019, Accepted Manuscript DOI: 10.1039/C9NJ03653A, PaperHuiping Wang, Libang He, Peng Zhang, Jie Zhang, Zhenhua Chen, Xiuli Ren, Xifan Mei Targeted delivery of therapeutic drug into cancer cells is a facile method to improve the therapeutic efficacy. Focused on this point, the doxorubicin (DOX) -loaded hydroxyapatite (HAP) nanorods consisting of... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
Chem. Commun., 2019, Accepted Manuscript DOI: 10.1039/C9CC05826E, CommunicationJia Li, Le Li Zeng, Kai Xiong, Thomas Wheildon Rees, Chengzhi Jin, Weijun Wu, Yu Chen, Liangnian Ji, Hui Chao Platinum-resistant cancer cells are sensitive to changes in the levels of reactive oxidative species (ROS). Herein, we design a biotin-modified Ru(II) complex as photosensitizer (denoted as Ru-Biotin). Ru-Biotin can selectively... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Chem. Commun., 2019, Accepted Manuscript DOI: 10.1039/C9CC03379C, CommunicationAnnemiek Uvyn, Ruben De Coen, Olivier De Wever, Kim Deswarte, Bart Lambrecht, Bruno De Geest Triggering antibody-mediated innate immune mechanisms to kill cancer cells is an attractive therapeutic avenue. In this context, recruitment of endogenous antibodies to the cancer cell surface could be a viable... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Publication date: Available online 19 August 2019Source: The American Journal of SurgeryAuthor(s): Katherine Bingmer, Asya Ofshteyn, David Dietz, Sharon L. Stein, Emily SteinhagenAbstractBackgroundImmunosuppressed patients have an increased risk of developing anal cancer, but little data exists regarding outcomes of this population.MethodsA retrospective review of anal cancer patients at a single academic institution from 2006-2017 was performed.Results19 (14%) of 136 anal cancer patients were immunosuppressed. Immunosuppressed patients were more likely to be hypoalbuminemic (21% vs. 6%, p=0.025), less likely to complete c...
Source: The American Journal of Surgery - Category: Surgery Source Type: research
In conclusion, osmotic burst of inflated complement-damaged cells may occur, but these bursts are most likely a consequence of metabolic collapse of the cell rather than the cause of cell death. The Complement Cell Death Mediator: A Concerted Action of Toxic Moieties Membrane pores caused by complement were first visualized by electron microscopy on red blood cell membranes as large ring structures (22). Similar lesions were viewed on E. coli cell walls (23). Over the years, ample information on the fine ultrastructure of the MAC that can activate cell death has been gathered (24) and has been recently further examined (...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion: In our experience, 98.3% of 122 RDDs were completed. We found that RDD was safe and effective in this the largest series of RDD with chemotherapeutics in our country.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Platinum-based antineoplastic agents (platins) are the most frequently used chemotherapeutics in patients with a variety of cancers, such as ovarian, colorectal, endometrial, and pancreatic cancer among others, and their use is associated with an increase in drug hypersensitivity reactions (DHRs).1 In particular, 2 commonly used platins, oxaliplatin and carboplatin, have high rates of DHR: carboplatin DHR rates range from 9% to 27%, whereas oxaliplatin DHR rates are as high as 25% and typically manifest between the fifth and seventh infusions.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Letter to the Editor Source Type: research
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Endometrial Cancer | OBGYN | Ovarian Cancer | Ovaries | Study